Publications and Presentations

Filter by:

All Molecules

Domvanalimab (AB154)

Quemliclustat (AB680)

Etrumadenant (AB928)

Zimberelimab (AB122)

Casdatifan (AB521)

AB598 (CD39)

AB801 (AXL)

AB308 (TIGIT)

HPK1

STUB1

DGK

Discovery Pipeline

FLT3

Other

All Conferences/Journals

AACR

ACS

ASCPT

ASCO

Cancer Research

Discovery on Target

ENA

ESMO

FOCiS

Immunology 2022

Immuno US 2023

IKCS

KCRS

Keystone

Manuscripts

MCI

PBSS Advances in Cancer Therapeutics Symposium

SABCS

SITC

SLAS

Sort by:

Date

Conferences/Journals

No results found

November 6-10, 2024

Society for Immunotherapy of Cancer (SITC)

Randomized Study of Domvanalimab Combined With Zimberelimab in Front-Line, PD-L1–High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Results From ARC-10 Part 1

Jarushka Naidoo, et al.

November 6-10, 2024

Society for Immunotherapy of Cancer (SITC)

The Adenosine Receptor Antagonist Etrumadenant Reduces Tumor Adenosine-Regulated NR4A Gene Expression and Increases mCRC Inflammation in Patients From the ARC-9 Trial

Ji Yun Kim, et al.

November 6-10, 2024

Society for Immunotherapy of Cancer (SITC)

TIGIT Blockade By Monoclonal Antibodies Promotes T Cell Activation and Anti-tumor Activity That is Not Dependent on a Functionalized Fc Domain

Didi S. Zhu, et al.

October 23-25, 2024

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

Casdatifan in Patients With Previously Treated Clear Cell Renal Cell Carcinoma and Other Solid Tumors: Preliminary Results From ARC-20, a Phase 1, Open-Label, Dose Escalation and Expansion Study

Toni K. Choueiri, et al.

October 23-25, 2024

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

AB801, a Potent and Highly Selective Clinical Stage AXL Inhibitor, Sensitizes Tumors to Standard of Care Therapies

Susan L. Paprcka, et al.

October 23-25, 2024

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

AB521 (Casdatifan) Potently and Selectively Inhibits Hypoxia-Inducible Factor 2 Alpha (HIF-2α) Dependent Pro-Tumorigenic Activity

Patrick G. Schweickert, et al.

October 23-25, 2024

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α, Confirms Best-in-class Potential in Treatment of Renal Cell Carcinoma

Mohammad Ghasemi, et al.

September 15-18, 2024

AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research

Quemliclustat (CD73 Inhibitor) Reduces Adenosine-Regulated NR4A Gene Expression and Increases mPDAC Inflammation in Patients from the ARC-8 Trial

Ji Yun Kim, et al.

August 18-22, 2024

American Chemical Society

Discovery and Characterization of AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor

Ken Lawson, et al.

July 11–12, 2024

Kidney Cancer Research Summit

Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer

Mohammad Ghasemi, et al.

June 18, 2024

Molecular Cancer Therapeutics

Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors

Amy E. Anderson, et al.

May 31–June 4, 2024

American Society of Clinical Oncology (ASCO) Annual Meeting

Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 Study of Domvanalimab, Zimberelimab, and FOLFOX in First-Line (1L) Advanced Gastroesophageal Cancer

Yelena Y. Janjigian, M.D.

May 31–June 4, 2024

American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract #3508: ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)

Zev A. Wainberg, M.D.

April 18, 2024

Cancer Research

Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

Dana Piovesan, et al.

April 5-10, 2024

American Association for Cancer Research (AACR)

Inhibition of CD39 by AB598 Increases Extracellular ATP Resulting in Activation of Myeloid Cells and T Cells to Enhance Anti-Tumor Immunity

Ke Jin, et al.

April 5-10, 2024

American Association for Cancer Research (AACR)

Inhibition of ULK1/2-Mediated Autophagy Augments Antigen Processing and Presentation in STK11-mutant NSCLC

Samantha C. Schwager, et al.

April 5-10, 2024

American Association for Cancer Research (AACR)

Cbl Inhibition Increases the Response of Cytotoxic T Cells to Sub-Optimal Stimulation and Drives Enhanced Anti-Tumor Responses Alone or in Combination with PD-1 Blockade

Lίvia Yamashiro, et al.

April 5-10, 2024

American Association for Cancer Research (AACR)

Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

Kyu-pyo Kim, et al.

March 27-29, 2024

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Food and Co-administration of Acid Reducing Agents (ARAs) Have No Clinically Significant Effect on the Pharmacokinetics of Etrumadenant, a Novel Dual Adenosine Receptor Antagonist –Population Pharmacokinetic (PopPK) and Physiologically-Based (PBPK) Modeling Exploration

Jordon Johnson, et al.

March 27-29, 2024

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Multiple Elimination Pathways are Responsible for the Elimination of Etrumadenant after Oral Administration of [14C]-Etrumadenant to Humans

Lilian W. Adeojo, et al.

March 27-29, 2024

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Population Pharmacokinetic (PopPK) Model of AB521 (Casdatifan), a Small Molecule Inhibitor of HIF-2α, in Healthy Participants

Mohammad Ghasemi, et al.

March 18-21, 2024

Keystone Symposia Conference

Fc-silent Anti-TIGIT Antibodies Offer Best-in-Class Potential By Potentiating Robust CD8+T Cell-Mediated Anti-tumor Immunity Without Peripheral Regulatory T Cell Depletion

Kelsey E. Gauthier, Ph.D.

March 17-21, 2024

American Chemical Society Spring Meeting

Discovery and Optimization of HIF-2α Inhibitors

Artur K Mailyan, et al.

February 3-7, 2024

Society for Laboratory Automation and Screening (SLAS)

Development of Cell-based Assays for the Identification and Characterization of Inhibitors of Mutant G323E Hypoxia Inducible Factor-2α (HIF-2α)

Cesar Meleza, et al.

February 3-7, 2024

Society for Laboratory Automation and Screening (SLAS)

A novel cell-based assay to identify the FLT3 kinase construct used in enzyme assays that best represents the activity of cellular FLT3

Lunda Shen, et al.

January 27-30, 2024

Midwinter Conference of Immunologists at Asilomar (MCI)

Inhibition of AXL Signaling with AB801 Augments Anti-Tumor Immune Responses

Jhansi L. Leslie, et al.

January 18-20, 2024

2024 Gastrointestinal Cancers Symposium (ASCO GI)

ARC‑8: Phase 1/1b Randomized Study of Quemliclustat + Gemcitabine / Nab‑Paclitaxel ± Zimberelimab in Patients With Treatment‑Naive Metastatic Pancreatic Adenocarcinoma

Zev A. Wainberg, et al.

November 7, 2023

ASCO Plenary Series

Abstract 433248: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.

Yelena Y. Janjigian, M.D.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

AB598, a CD39 Inhibitory Antibody, Promotes Immune-Mediated Tumor Control

Julie Clor, et al.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

Dual Inhibition DGKα and DGKζ Increases T Cell and NK Cell Activity

Patrick G. Schweickert, et al.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

Fc-silent Anti-TIGIT Antibodies Potentiate Anti-tumor Immunity Without Depleting Regulatory T Cells

Kelsey E. Gauthier, et al.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

Inhibition of AXL Signaling with AB801 Augments Anti-Tumor Immune Responses

Jhansi L. Leslie, et al.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

STUB1 regulates IFNGR1 expression and IFNG sensitivity in human tumor cell lines

Bonny D. Alvarenga, et al.

November 1-5, 2023

Society for Immunotherapy of Cancer (SITC)

Combined Administration of the Dual A2aR/A2bR Antagonist Etrumadenant with a Reduced Chemotherapy Regimen Leads to Enhanced Tumor Efficacy and Survival

Sachie Marubayashi, et al.

October 11-15, 2023

EORTC-NCI-AACR

Partially Open Conformation of The G323E Mutated HIF-2α PASB Domain Captured By X-ray Crystallography

Steven Shia, et al.

October 12-13, 2023

Immuno US 2023

Inhibition of CD39 to Promote Anti-Tumor Immune Responses

Christine Bowman, Ph.D.

September 25-28, 2023

Discovery on Target

Discovery and Optimization of HIF-2α Inhibitors

Ken Lawson

September 21, 2023

PBSS Advances in Cancer Therapeutics Symposium 2023

F-c Silent anti-TIGIT Antibodies Potentiate Anti-Tumor Immunity Without Depleting Regulatory T Cells

Kelsey E. Gauthier, Ph.D.

June 24-27, 2023

AACR Special Conference: Advances in Kidney Cancer Research

Targeting Hypoxia Inducible Factor (HIF)-2α With AB521, a Novel and Potent Small Molecule HIF-2α Inhibitor, for the Treatment of Clear Cell Renal Cell Carcinoma

Paul G. Foster, et al.

April 14-19, 2023

American Association for Cancer Research (AACR)

Characterization of AB598, a Therapeutic Anti-Human CD39 Antibody for the Treatment of Cancer

Amy E. Anderson, et al.

April 14-19, 2023

American Association for Cancer Research (AACR)

AB801 is a Highly Potent and Selective AXL Kinase Inhibitor that Demonstrates Significant Anti-Tumor Activity

Susan L Paprcka, et al.

March 26-30, 2023

American Chemical Society Spring Meeting

Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors

Corinne N. Foley, et al.

March 26-30, 2023

American Chemical Society Spring Meeting

Discovery and characterization of orally bioavailable, potent, and selective small-molecule AXL kinase inhibitors for cancer therapy

Shiwei Qu, et al.

March 22-24, 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Use of a population pharmacokinetic modelling and simulation approach to identify flat doses of domvanalimab in phase 3 studies

Ayyappa Chaturvedula, et al.

March 22-24, 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Limited drug interaction supported by a clinical drug interaction study and physiologically based pharmacokinetic modeling of etrumadenant (AB928), a novel dual adenosine receptor antagonist, under coadministration with a strong CYP3A4 and p-glycoprotein inhibitor (itraconazole) in healthy participants

Lian Zhou, et al.

March 6-8, 2023

ESMO Targeted Anticancer Therapies Congress

Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma

Kelsey E. Gauthier, et al.

January 28-31, 2023

61st Midwinter Conference of Immunologists at Asilomar

Rationale for the combination of AB598, a CD39 blocking antibody, and chemotherapy for the treatment of solid tumors

Kaustubh Parashar, et al.

December 20, 2022

ASCO Plenary Series

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)

Melissa Johnson, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

HPK1 inhibition relieves suppression downstream of TCR activation to drive enhanced cytokine production, an effect that is further enhanced by immune checkpoint blockade

Rajesh Singh, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for a full chemotherapy regimen.

Daniel DiRenzo, et al.

November 8-12, 2022

Society for Immunotherapy of Cancer (SITC)

AB598, a therapeutic anti-human CD39 antibody, binds and inhibits CD39 enzymatic activity in vivo to promote anti-tumor immunity

Kaustubh Parashar, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

HIF-2α inhibitor AB521 modulates erythropoietin levels in healthy volunteers following a single oral dose

Kai H. Liao, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics

Susan L. Paprcka, et al.

October 26-28, 2022

EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium

Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801

Dillon H. Miles, et al.

October 21-24, 2022

AACR Tumor Immunology & Immunotherapy Symposium

HPK1 inhibition enhances T cell activation and relieves the immunosuppressive effects of extracellular substances found in the tumor microenvironment

Bindi Patel, et al.

October 21-24, 2022

AACR Tumor Immunology & Immunotherapy Symposium

AB598, a therapeutic anti-CD39 antibody, elevates ATP and increases immunogenicity in the tumor microenvironment

Kaustubh Parashar, et al.

June 21-24, 2022

Federation of Clinical Immunology Societies (FOCiS)

Anti-TIGIT Antibodies Promote Immune Activation in Combination with Immunotherapeutic Agents

Dana Piovesan, et al.

June 21-24, 2022

Federation of Clinical Immunology Societies (FOCiS)

Inhibiting TIGIT to Promote Anti-Tumor Immunity

Dana Piovesan, et al.

June 2022

Molecular Cancer Therapeutics

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

Dana Piovesan, et al.

May 6-10, 2022

Immunology 2022

Anti-TIGIT Antibodies Promote Immune Activation Relevant to Targeting Stem-like and Tumor-specific T Cells in Combination With Anti-PD-1

Kelsey E. Gauthier, et al.

April 22-24, 2022

International Kidney Cancer Symposium (IKCS)

AB521 is a Novel and Potent Clinical-Stage HIF-2a Inhibitor for the Treatment of Renal Cell Carcinoma

Kelsey E. Gauthier, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

Dual A2aR/A2bR antagonism with etrumadenant (AB928) eliminates the suppressive effects of adenosine on immune and cancer cells in the tumor microenvironment

Sachie Marubayashi, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

Inhibition of CD39 Results in Elevated ATP and Activation of Myeloid Cells to Promote Anti-Tumor Immunity

Christine Bowman, et al.

April 8-13, 2022

American Association for Cancer Research (AACR)

HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment

Rajesh Singh, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Population Pharmacokinetics of Zimberelimab (AB122) and Dose Justification by Model Informed Drug Development (MIDD) Approach

Xiaoying Yu, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Population Pharmacokinetics and Pharmacodynamics of Etrumadenant (AB928) in Healthy Volunteers and Cancer Patients

Huali Wu, et al.

March 16-18, 2022

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

A Mechanistic Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Quemliclustat (AB680), a Small-Molecule Inhibitor of CD73, in Healthy Volunteers and Patients with Gastrointestinal Malignancies

Kai H. Liao, et al.

March 7-8, 2022

ESMO Targeted Anticancer Therapies Congress

AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2⍺ Inhibitor, for the Treatment of Renal Cell Carcinoma

Kenneth Lawson, et al.

November 10-14, 2021

Society for Immunotherapy of Cancer (SITC)

AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-Tumor Immunity Alone and in Combination With Other I-O Therapeutic Agent

Dana Piovesan, et al.

October 7-10, 2021

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

AB521 potently and selectively inhibits pro-tumorigenic gene transcription by Hypoxia-Inducible Factor (HIF)-2⍺ in vitro and in vivo

Dana Piovesan, et al.

October 7-10, 2021

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Potent and selective AXL tyrosine kinase inhibition demonstrates significant anti-tumor efficacy in combination with standard of care therapeutics in preclinical models

Susan L Paprcka, et al.

June 4-8, 2021

American Society of Clinical Oncology (ASCO) Annual Meeting

ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study to Evaluate Efficacy and Safety of Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Castrate-Resistant Prostate Cancer

Sumit K. Subudhi, et al.

April 9-14, 2021

Annual Meeting of the American Association of Cancer Research (AACR)

Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2⍺ inhibitor

Kenneth V. Lawson, et al.

April 9-14, 2021

Annual Meeting of the American Association of Cancer Research (AACR)

ARC-3: Updated results of Etrumadenant (AB928) + mFOLFOX-6 in patients with metastatic colorectal cancer

M. Cecchini, et al.

January 15-17, 2021

2021 Gastrointestinal Cancers Symposium (ASCO GI)

ARC-8: Phase 1/1b Study to Evaluate Safety and Tolerability of AB680 + Chemotherapy + Zimberelimab (AB122) in Patients with Treatment-Naive Metastatic Pancreatic Adenocarcinoma

GA Manji, et al.

January 15-17, 2021

2021 Gastrointestinal Cancers Symposium (ASCO GI)

ARC-9: Phase 1b/2 Study to Evaluate Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

M.Cecchini, et al.

December 8-11, 2020

San Antonio Breast Cancer Symposium (SABCS)

ARC-2: Efficacy and Safety of Etrumadenant (AB928) + Pegylated Liposomal Doxorubicin (PLD) ± Eganelisib (IPI-549) in Participants with Metastatic Ovarian and Triple Negative Breast Cancer

J Sachdev, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Emerging Insights on the Association of Tumor Molecular Phenotype with Clinical Benefit in Metastatic Colorectal Cancer (mCRC) Subjects Treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6)

Akshata R Udyavar, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Potent and Selective Inhibition of AXL Receptor Tyrosine Kinase for the Treatment of Cancer

Susan L. Paprcka, et al.

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

Novel, Potent, and Selective Inhibitors of Hypoxia-Inducible Factor (HIF)-2α Reverse Pro-tumorigenic Transcriptional Programming in Cancer, Stromal, and Immune Cells

Dana Piovesan, et al.

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

Discovery and Characterization of Potent and Selective AXL Receptor Tyrosine Kinase Inhibitors for Cancer Therapy

Dillon H. Miles, et al.

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

Discovery and Characterization of Novel, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2a Inhibitors

Kenneth V Lawson, et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-4: Efficacy and Safety of Etrumadenant (AB928) plus Carboplatin, Pemetrexed and a PD-1 Antibody in Participants with Metastatic Non-Small Cell Lung Cancer

A Spira , et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Castrate-Resistant Prostate Cancer

SK Subudhi , et al.

September 19-21, 2020

European Society for Medical Oncology (ESMO) Congress

ARC-7: A Phase 2 Study to Evaluate the Safety and Efficacy of Zimberelimab Monotherapy and Domvanalimab (AB154) + Zimberelimab +/- Etrumadenant (AB928) in Front-Line, PD-L1-High Expressing, Non-Small Cell Lung Cancer

A Chaudhry, et al.

June 22-24, 2020

Annual Meeting of the American Association of Cancer Research (AACR)

Audio: Efficacy and safety of etrumadenant plus modified FOLFOX-6 in participants with metastatic colorectal cancer: initial results at the recommended dose for expansion (ARC-3).

M Cecchini, et al.

Play Audio - 4:56

June 22-24, 2020

Annual Meeting of the American Association of Cancer Research (AACR)

Poster: Efficacy and safety of etrumadenant plus modified FOLFOX-6 in participants with metastatic colorectal cancer: initial results at the recommended dose for expansion (ARC-3).

M Cecchini, et al.

February 13-15, 2020

American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium

A phase 1b/2, open-label, platform study evaluating the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castrate resistant prostate cancer (ARC-6).

Wise DR, et al.

January 23-25, 2020

Gastrointestinal Cancers Symposium (ASCO)

A phase 1 study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies (ARC-8).

Bendell J, et al.

January 19-24, 2020

Keystone Symposia Conference

Selective inhibition of hypoxia-inducible factor (HIF)-2α for the treatment of cancer.

Piovesan D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

A_2bR contributes to adenosine-mediated immunosuppression, which is relieved by the dual A_2a/A_2b antagonist etrumadenant.

DiRenzo D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Phase 1 safety trial in healthy volunteers of Quemliclustat (AB680), a small molecule inhibitor of CD73 and rationale for combination therapy in patients with gastrointestinal malignancies.

Ashok D, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Characterization of domvanalimab, a humanized, non-depleting α-TIGIT antibody undergoing clinical evaluation in subjects with advanced solid tumors.

Anderson AE, et al.

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

Targeting immune-suppressive myeloid cell pathways for the treatment of cancer.

Banuelos J, et al.

October 26-30, 2019

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics

Novel, potent, and selective hypoxia-inducible factor-2α (HIF-2α) antagonists.

Gauthier KES, et al.

September 27 – October 1, 2019

European Society for Medical Oncology (ESMO) Congress

Phase 1 evaluation of etrumadenant, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies.

Powderly J, et al.

July 23, 2019

Biochemistry

An exceptionally potent inhibitor of human CD73.

Bowman CE, et al.

May 31 – June 4, 2019

American Society of Clinical Oncology (ASCO) Annual Meeting

Etrumadenant, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients with advanced tumors: preliminary results from ongoing phase 1 studies.

Powderly J, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers.

Udyavar A, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Methods for assessment of the “adenosine fingerprint” in clinical trials of etrumadenant.

DiRenzo D, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy.

Ashok D, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Characterization of domvanalimab, a humanized α-TIGIT antibody, for use in combination therapies.

Anderson AE, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Longitudinal monitoring of neoepitope-specific T cell repertoires in patient blood following cancer immunotherapy.

Peng S, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer.

Eckard SC, et al.

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

Inhibiting CD73 and KRAS enhances the effect of anti-PD-1 therapy in a KRAS^G12C/TP53^R172H/+ pancreatic cancer model.

Le TM, et al.

March 10-14, 2019

Keystone Symposia Conference C2

Oncogene-driven regulation of adenosine pathway expression in multiple cancers.

Udyavar AR, et al.

December 19, 2018

Investigational New Drugs

Safety, tolerability, and pharmacology of etrumadenant, a novel dual adenosine receptor antagonist, in a randomized, phase 1 trial in healthy volunteers.

Seitz L, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Preclinical characterization of domvanalimab, a fully humanized anti-TIGIT antibody, for use in combination therapies.

Anderson AE, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Development of a robust, simplified method to measure receptor occupancy in peripheral blood from patients treated with a novel anti-PD-1 agent, AB122.

Ashok D, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist etrumadenant.

DiRenzo D, et al.

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity.

Jaen J, et al.

Combining To Cure®

The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established.

Publications

Explore More